Tech Company Financing Transactions
Kesios Therapeutics Funding Round
On 12/3/2015, Kesios Therapeutics announced $28.4 million in Series A funding from Abingworth, Imperial Capital Group and SV Health Investors.
Transaction Overview
Company Name
Announced On
12/3/2015
Transaction Type
Venture Equity
Amount
$28,420,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
30 Broad St. Great Cambourne
Cambridge Cambridgeshire, CB23 6HJ
UK
Cambridge Cambridgeshire, CB23 6HJ
UK
Phone
Undisclosed
Website
Email Address
Overview
Kesios Therapeutics Limited is a UK-based biotechnology company developing novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paolo Paoletti
Chief Medical Officer
Jane Robertson
Chief Operating Officer
Dayle Hogg
Chief Scientific Officer
Peter Charlton
Browse more venture capital transactions:
Prev: 12/3/2015: Knocki venture capital transaction
Next: 12/3/2015: Velicept Therapeutics venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs